个人简介
赵玉军, 中国科学院上海药物研究所研究员,课题组长。2003年本科毕业于江苏省苏州大学化学化工学院，2019年研究生毕业于新加坡南洋理工大学获有机化学博士学位，2009-2015 年在美国密西根大学癌症中心从事博士后研究。主要从事的激酶和蛋白质相互作用小分子抑制剂的设计合成及生物活性研究。主要研究蛋白相互作用靶点包括：MDM4/p53、BFL1/BH3、PD-L1/PD-1、BET-Bromodomain/Histone、TEAD/YAP1; 激酶靶点包括NIK、ASK1、EGFR等激酶抑制剂作为靶向药物分子。以通讯作者或第一作者在Cancer Cell, J. Am. Chem. Soc., J. Med. Chem., FASEB J., Eur. J. Med. Chem.等国际重要学术刊物发表论文40余篇；申请PCT专利7项、中国专利11项，获中国授权发明专利3项、获美国授权发明专利8项；主持“重大新药创制”科技重大专项、国家自然科学基金面上项目、中国科学院战略性先导专项(A类)等多项省部级以上重点科研项目。
工作经历
2008.6–2009.5 新加坡南洋理工大学,Research Officer
2009.6–2015.3 美国密西根大学癌症中心,博士后
2015.3–今 中国科学院上海药物科学研究所,研究员
教育经历
2005/4-2009/1，南洋理工大学，数学与物理科学学院化学和化学生物学系，有机化学专业，博士研究生毕业
2003/8-2005/3，新加坡国立大学，理学院化学系，有机化学专业，博士研究生肄业
1999/9-2003/6， 苏州大学，化学化工学院，化学师范专业，本科学士
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Shiyan Zhang, Jianfeng Lou, Yafang Li, Feilong Zhou, Ziqin Yan, Xilin Lyu, Yujun Zhao*, Recent progress and clinical development of inhibitors that block MDM4/p53 protein-protein interactions, Journal of Medicinal Chemistry, 2021, 64, 10621–10640. (IF: 7.44, Year 2021)
Chenglong Liu, Feilong Zhou, Ziqin Yan, Lian Shen, Xichen Zhang, Fenglian He, Xiaojie Lu, Heng Wang, Ker Yu, Yujun Zhao*, Di Zhu*, Discovery of a novel, potent, and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy, British Journal of Pharmacology, 2021, 178, 2651-2670. (IF: 8.73, Year 2021)
Xuan Wang, Jiaxiang Liu, Ziqin Yan, Xiaohong Liu, Sixiu Liu, Yanrui Suo, Weiwei Lu, Jinfeng Yue, Kaixian Chen, Hualiang Jiang, Yujun Zhao*, Mingyue Zheng*, Dongcheng Dai*, Xiaojie Lu*, Diversified strategy for the synthesis of DNA-encoded oxindole libraries, Chemical Science, 2021, 12, 2841-2847. (IF: 9.82, Year 2021)
Jing Cheng, Xuexin Feng, Zhiqiang Li, Feilong Zhou, Jin-Ming Yang, Yujun Zhao*, Pharmacological inhibition of NF-κB-Inducing Kinase (NIK) with small molecules for the treatment of human diseases, RCS Medicinal Chemistry, 2021, 12, 552-565.
Xian Zhou, Xuexin Feng, Dachi Wang, Deheng Chen, Gaoxing Wu, Ziqin Yan, Xilin Lyu, Huan Wang, Jin-Ming Yang,* Yujun Zhao*, Synthesis and Bioactivity Studies of Covalent Inhibitors Derived from (-)-Chaetominine, Journal of Molecular Structure, 2021, 1241, 130694. (IF: 3.19, Year 2021)
Zhiqiang Li, Xinzhi Li, Ming-Bo Su, Li-Xin Gao, Yu-Bo Zhou, Bingchuan Yuan, Xilin Lyu, Ziqin Yan, Chujiao Hu, Hao Zhang, Cheng Luo, Zheng Chen*, Jia Li*, Yujun Zhao*, Discovery of a potent and selective NF-κB-inducing kinase (NIK) inhibitor that has anti-inflammatory effects in vitro and in vivo, Journal of Medicinal Chemistry, 2020, 63, 4388-4407. (IF: 7.44, Year 2021)
Shiyan Zhang, Chaoying Huang, Xilin Lyu, Peipei Wang, Yi Zang, Zengtao Wang, Huan Wang, Jia Li*, Yujun Zhao*, Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal -regulating kinase 1 (ASK1), European Journal of Medicinal Chemistry, 2020, 195, 112277. (IF: 6.51, Year 2021)
Xinzhi Li, Yongsen Wu, Yue Song, Na Ding, Min Lu, Linna Jia, Yujun Zhao, Ming Liu, Zheng Chen*, Activation of NF-kB-inducing kinase in islet β-cells causes β-cell failure and diabetes, Molecular Therapy, 2020, 2430-2441. (IF: 11.45, Year 2021)
Deheng Chen, Tian Lu, Ziqin Yan, Wenchao Lu, Feilong Zhou, Xilin Lyu, Biling Xu, Hualiang Jiang, Kaixian Chen, Cheng Luo*, and Yujun Zhao*, Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins, European Journal of Medicinal Chemistry, 2019, 182, 111633. (IF: 6.51, Year 2021)
Erbao Zhao, Feilong Zhou, and Yujun Zhao*, Lewis Acids Promoted 3+2 Cycloaddition of Oxaziridines and Cyclic Allylic Alcohols through Carbonyl Imine Intermediates, Journal of Organic Chemistry, 2019, 84 (7), 4282–4293. (IF: 4.35, Year 2021 )
Deheng Chen, Dexiang Guo, Ziqin Yan, Yujun Zhao*, Allenamide as a bioisostere of acrylamide in design and synthesis of targeted covalent inhibitors Med. Chem. Commun. 2018, 9, 244-253. (IF: 3.59, Year 2021)
Feilong Zhou, Erbao Zhao, Ziqin Yan, Deheng Chen, Yujun Zhao*, Synthesis of 3,4-diarylsubstituted hexahydro-1H-indoles, Tetrahedron Letters, 2018, 59, 1871-1874. (IF: 2.41, Year 2021)
Xiaomeng Ren, Xinzhi Li, Linna Jia, Deheng Chen, Hai Hou, Liangyou Rui, Yujun Zhao*, Zheng Chen*, A small-molecule inhibitor of NF-kB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury, FASEB Journal. 2017, 2, 711-718. (IF: 5.19, Year 2021)
京公网安备 11010802027423号